Eligible patients with previously untreated limited-stage SCLC received one cycle of etoposide plus cisplatin ( intravenous etoposide @ mg/m ( @ ) on days @-@ ; intravenous cisplatin @ mg/m ( @ ) on day @ ) plus AHTRT ( @ Gy twice daily , @ days a week , total @ Gy over @ weeks ) .